MyFinsight
Home
Blog
About
Back
Cash Flow
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)
source: myfinsight.com
Net change in cash
and cash...
-$775,220
(58.52%↑ Y/Y)
Stock-based compensation
$33,000
(41.12%↑ Y/Y)
Prepaid expenses
-$13,927
(-429.24%↓ Y/Y)
Non-cash lease expense
$2
(-99.37%↓ Y/Y)
Net cash flows from
operating activities
-$775,220
(58.52%↑ Y/Y)
Canceled cashflow
$46,929
Net loss
-$613,933
(52.51%↑ Y/Y)
Accounts payable and
other current...
-$208,216
(65.04%↑ Y/Y)
Back